文献速递慢性静脉疾病

3D SYM VEIN症状评估工具的验证

Validation of the 3D SYM VEIN Symptom Assessment Tool.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2020-07-30

前瞻性队列研究纳入35例接受大隐静脉切除术的慢性静脉疾病患者,术前及术后4周用r-VCSS、CIVIQ-20和SYM VEIN 3D系统评估。3D总分信度良好(Cronbach's alpha 0.85),与r-VCSS和CIVIQ-20显著相关,术后显著下降但变化幅度小于r-VCSS。

要点

  • SYM VEIN 3D总分信度良好,Cronbach's alpha为0.85。
  • 3D总分与r-VCSS(rho .46, p = .005)和CIVIQ-20(rho .65, p < .001)显著相关。
  • 术后3D总分中位数从31降至6(83.8%降幅,p < .001),反应性优良但低于r-VCSS。

核心结论

  • SYM VEIN 3D总分具有良好的信度、结构效度和优良的反应性,但术后变化幅度小于r-VCSS。

研究设计与样本

  • 前瞻性队列研究,纳入35例连续接受大隐静脉切除术的慢性静脉疾病患者,术前和术后4周评估。

主要发现

  • 3D总分信度良好,Cronbach's alpha为0.85。
  • 主成分分析识别出三组症状,组内高度相关,提示结构效度 adequate。
  • 3D总分与r-VCSS(rho .46, p = .005)和CIVIQ-20(rho .65, p < .001)显著相关,提示收敛效度 adequate。
  • 术后3D总分及除两个症状外所有个体静脉症状评分显著降低(p < .001),提示反应性优良。
  • 3D总分中位数从31降至6(83.8%降幅,p < .001),r-VCSS中位数从6降至0(100%降幅,p < .001),CIVIQ-20中位数从24降至14(40%降幅,p < .001)。

关键数值与推荐

  • Cronbach's alpha 0.85。
  • 3D总分与r-VCSS相关系数rho .46(p = .005),与CIVIQ-20相关系数rho .65(p < .001)。
  • 术后3D总分中位数从31降至6(83.8%降幅,p < .001)。
  • r-VCSS与CIVIQ-20相对于3D总分的百分比变化中位数差异显著(p = .005和p < .001)。

临床怎么用

  • SYM VEIN 3D总分可用于慢性静脉疾病患者症状评估,信度和效度良好。
  • 术后症状改善评估中,3D总分变化幅度小于r-VCSS,解读时需注意。

局限性

  • 样本量较小(35例),仅纳入接受大隐静脉切除术的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim was to validate the SYM VEIN consensus 3D scoring tool in chronic venous disease (CVD). METHODS: This was a prospective cohort study with a total of 35 consecutive patients with CVD. Patients with CVD undergoing saphenectomy were assessed with the revised Venous Clinical Severity Score (r-VCSS), the CIVIQ-20 quality of life score questionnaire, and the SYM VEIN consensus statement 3D system, pre-operatively and four weeks post-operatively. The total 3D score was tested for reliability, construct validity, and responsiveness. RESULTS: The total 3D score demonstrated good reliability and internal consistency (Cronbach's alpha 0.85). Principal component analysis identified three groups of symptoms (paraesthesia, burning pain, and pruritus, vs. heaviness, sensation of swelling and aching/pain, vs. restless leg and throbbing pain) demonstrating a high intragroup correlation and likely to share similar pathophysiology, indicative of adequate construct validity. The total 3D score showed a significant correlation with r-VCSS and CIVIQ-20 score (rho .46, p = .005 and rho .65, p < .001, respectively) indicative of adequate convergent validity. After saphenectomy, significant reductions (p < .001) of the total 3D, and 3D scores for all but two individual venous symptoms were observed, indicative of excellent responsiveness. Median total 3D score was reduced from 31 to 6 (83.8% decrease, p < .001), median r-VCSS was reduced from 6 to 0 (100% decrease, p < .001), and median CIVIQ-20 score was reduced from 24 to 14 (40% decrease, p < .001). The difference of median percentage change between r-VCSS and CIVIQ-20 score vs. total 3D score was significant (p = .005 and p < .001, respectively). CONCLUSION: The total SYM VEIN 3D score has good reliability, construct validity and excellent responsiveness, although less prone to change after saphenectomy compared with r-VCSS.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Kakkos SK, Papageorgopoulou CP, Nikolakopoulos KM, et al. Validation of the 3D SYM VEIN Symptom Assessment Tool. Eur J Vasc Endovasc Surg. 2020. PMID: 32739105. doi:10.1016/j.ejvs.2020.06.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。